FAST NEWS: CStone licenses PD-1 cancer drug to 3SBio for China
The latest: CStone Pharmaceuticals (2616.HK) announced Wednesday that it has exclusively licensed Shenyang Sunshine Pharmaceutical, a subsidiary of 3SBio Inc. (1530.HK), to develop, register, manufacture and commercialize its anti-PD-1 antibody Nofazinlimab…
FAST NEWS: 3SBio Sees Profit Doubling on Surging Revenues
The latest: 3SBio Inc. (1530.HK) released a positive profit forecast on Monday evening, estimating its net profit rose 100% to 120% for 2021, while its profit attributable to equity shareholders…
